Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aethlon Medical ( (AEMD) ) has provided an update.
On October 16, 2025, Aethlon Medical received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its stock price was below $1.00 for 30 consecutive business days. In response, the company has requested a hearing and implemented a 1-for-10 reverse stock split to regain compliance, with its stock continuing to trade under the symbol ‘AEMD’ while monitoring its bid price to maintain its Nasdaq listing.
The most recent analyst rating on (AEMD) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Aethlon Medical stock, see the AEMD Stock Forecast page.
Spark’s Take on AEMD Stock
According to Spark, TipRanks’ AI Analyst, AEMD is a Underperform.
Aethlon Medical’s overall stock score is low due to significant financial challenges, including persistent losses and cash flow issues. The technical indicators suggest negative momentum, and the valuation is unattractive given the negative P/E ratio and lack of dividends. While the earnings call presented some positive strategic efforts, such as cost reduction and trial advancements, the hurdles in clinical trials and financial constraints weigh heavily on the stock’s outlook.
To see Spark’s full report on AEMD stock, click here.
More about Aethlon Medical
Aethlon Medical, Inc. operates in the medical technology industry, focusing on developing therapeutic technologies to address unmet needs in health care.
Average Trading Volume: 305,893
Technical Sentiment Signal: Sell
Current Market Cap: $4.19M
For detailed information about AEMD stock, go to TipRanks’ Stock Analysis page.